Diagnosis and management of chronic obstructive pulmonary disease: The swiss guidelines: Official guidelines of the swiss respiratory society

Respiration

Volumn 85, Issue 2, 2013, Pages 160-174

  Russi, E W ^a   Karrer, W ^d   Brutsche, M ^e   Eich, C ^b   Fitting, J W ⁱ   Frey, M ^f   Geiser, T ^j   Kuhn, M ^g   Nicod, L ⁱ   Quadri, F ^h   Rochat, T ^k   Steurer Stey, C ^c   Stolz, D ^l  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Private Practice   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d Luzerner Hohenklinik   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Klinik Barmelweid   (Switzerland)

^g KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^h Ospedale Regionale Bellinzona e Valli   (Switzerland)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

^j UNIVERSITY OF BERN   (Switzerland)

^k Divisions of the University Hospitals   (Switzerland)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

Chronic obstructive pulmonary disease; Diagnosis; Management; Swiss Guidelines; Treatment

Indexed keywords

ACETYLCYSTEINE; ALPHA 1 ANTITRYPSIN[_DDTH ALPHA 1 ANTITRYPSIN DEFICIENCY;_DDTH CHRONIC OBSTRUCTIVE LUNG DISEASE;_DCMPX PLACEBO;_DROUT INTRAVENOUS DRUG ADMINISTRATION;_DLNK CLINICAL TRIAL]; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOCISTEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; GLUCOCORTICOID; IMMUNOSTIMULATING AGENT; INDACATEROL; INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; PROCALCITONIN; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; MUCOLYTIC AGENT; PHOSPHODIESTERASE INHIBITOR; TOBACCO SMOKE;

ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY DIAGNOSIS; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOKALEMIA; IMMUNOSTIMULATION; INFLUENZA VACCINATION; LUNG FUNCTION TEST; LUNG RESECTION; LUNG TRANSPLANTATION; NUTRITIONAL SUPPORT; OXYGEN THERAPY; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT EDUCATION; PHYSICIAN; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RISK FACTOR; SELF CARE; TACHYCARDIA; THORAX RADIOGRAPHY; TREMOR; VACCINATION; ASTHMA; BRONCHOSCOPIC LUNG VOLUME REDUCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); ENVIRONMENTAL EXPOSURE; EXERCISE; FORCED EXPIRATORY VOLUME; NONINVASIVE VENTILATION; NUTRITION; OCCUPATIONAL EXPOSURE; PHARMACEUTICAL CARE; POSITIVE END EXPIRATORY PRESSURE; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL VOLUME; RESPIRATORY CARE; SMOKING; SMOKING CESSATION; SUBSTITUTION THERAPY; SUPPORT GROUP; TOTAL LUNG CAPACITY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALPHA 1-ANTITRYPSIN; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CONTINUOUS POSITIVE AIRWAY PRESSURE; EXERCISE; EXPECTORANTS; GLUCOCORTICOIDS; HUMANS; INFLUENZA VACCINES; OXIMETRY; OXYGEN INHALATION THERAPY; PATIENT EDUCATION AS TOPIC; PHOSPHODIESTERASE INHIBITORS; PNEUMOCOCCAL VACCINES; PNEUMONECTOMY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; RESPIRATORY THERAPY; RISK FACTORS; SELF CARE; SOCIAL SUPPORT; TOMOGRAPHY, X-RAY COMPUTED; WEIGHT GAIN;

EID: 84874043244     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000346025     Document Type: Article

References (126)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
2. Salvi SS, Barnes PJ: Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374: 733-743.
3. Schikowski T, Sugiri D, Ranft U, Gehring U, Heinrich J, Wichmann HE, Krämer U: Long-term air pollution exposure and living close to busy roads are associated with COPD in women. Respir Res 2005; 6:152.
4. Vogelmeier C, Buhl R, Criée CP, Gillissen A, Kardos P, Köhler D, Magnussen H, Morr H, Nowak D, Pfeiffer-Kascha D, Petro W, Rabe K, Schultz K, Sitter H, Teschler H, Welte T, Wettengel R, Worth H: Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnos-tik und Therapie von Patienten mit chro-nisch obstruktiver Bronchitis und Lungen-emphysem (COPD). Pneumologie 2007; 61:e1-e40.
5. O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G, Gervais A, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. Can Respir J 2008; 15(suppl A):1A-8A.
6. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London, National Clinical Guideline Centre, 2010. http://guidance. nice.org.uk/CG101/Guidance/ pdf/English.
7. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155:179-191.
8. The global strategy for diagnosis, management and prevention of COPD: GOLD. www.goldcopd.org (updated 2011).
9. Russi EW, Leuenberger P, Brändli O, Frey JG, Grebski E, Gugger M, Paky A, Pons M, Kar-rer W, Kuhn M, Rochat T, Schibli R, Solèr M, Wacker J: Management of chronic obstructive pulmonary disease: the Swiss guidelines. Official Guidelines of the Swiss Respiratory Society. Swiss Med Wkly 2002; 132: 67-78.
10. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK, Balmes JR: An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693-718.
11. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, Studnicka M, Bateman E, Anto JM, Burney P, Mannino DM, Buist SA, BOLD Collaborative Research Group: COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest 2011; 139: 752-763.
12. Mehta AJ, Miedinger D, Keidel D, Bettschart R, Bircher A, Bridevaux PO, Curjuric I, Kromhout H, Rochat T, Rothe T, Russi EW, Schikowski T, Schindler C, Schwartz J, Turk A, Vermeulen R, Probst-Hensch N, Künzli N, The SAPALDIA Team: Occupational exposure to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am J Respir Crit Care Med 2012; 185: 1292-1300.
13. Silva GE, Sherrill DL, Guerra S Barbee RA: Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59-65.
14. Stoller JK: Clinical features and natural history of severe alpha-1-antitrypsin deficiency. Chest 1997; 111: 123S-128S.
15. Stoller JK, Aboussouan LS: A review of al-pha-1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185: 246-259.
16. Smolonska J, Wijmenga C, Postma DS, Boezen HM: Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med 2009; 180: 618-631.
17. Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, Russi EW, Ackermann-Liebrich U, Leuenberger P: Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006; 61:671-677.
18. de Marco R, Accordini S, Marcon A, Cerveri I, Antó JM, Gislason T, Heinrich J, Janson C, Jarvis D, Kuenzli N, Leynaert B, Sunyer J, Svanes C, Wjst M, Burney P, European Community Respiratory Health Survey (ECRHS): Risk factors for chronic obstructive pulmonary disease in a European cohort of young adu lts. Am J Respir Crit Care Med 2011; 183: 891-897.
19. de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175:32-39.
20. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T: Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63:768-774.
21. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group: International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007; 370: 741-750.
22. Bridevaux PO, Probst-Hensch NM, Schindler C, Curjuric I, Felber Dietrich D, Braendli O, Brutsche M, Burdet L, Frey M, Gerbase MW, Ackermann-Liebrich U, Pons M, Tschopp JM, Rochat T, Russi EW: Prevalence of airflow obstruction in smokers and never smokers in Switzerland. Eur Respir J 2010; 36: 1259-1269.
23. Celli B, MacNee W, ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
24. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
25. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N: Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-654.
26. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Ren-nard S, Wouters EF, Wedzicha JA: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
27. Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
28. Celli B, Cote C, Marin J, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
29. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155:179-191.
30. Yawn BP, Enright PL, Lemanske RF Jr, Israel E, Pace W, Wollan P, Boushey H: Spirometry can be done in family physicians' offices and alters clinical decisions in management of asthma and COPD. Chest 2007; 132: 1162-1168.
31. Leuppi JD, Miedinger D, Chhajed PN, Buess C, Schafroth S, Bucher HC, Tamm M: Quality of spirometry in primary care for case finding of airway obstruction in smokers. Respiration 2010; 79: 469-474.
32. 1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63:1046-1051.
33. 1/FVC ! 0.70 to detect air way obstruction? No. Chest 2010; 138: 1037-1043.
34. 1/F VC ! 0.70 to detect a ir-way obstruction? Yes. Chest 2010; 138: 1040-1044.
35. Pelkonen M, Notkola IL, Tukiainen H, Ter-vahauta M, Toumilehto J, Nissinen A: Smoking cessation, decline in pulmonary function and total mortality: a 30-year follow-up study among the Finnish cohorts of the Seven Countries Study. Thorax 2001; 56: 703-707.
36. Chandler MA, Rennard SI: Smoking cessation. Chest 2010; 137:428-435.
37. Humair JP, Cornuz J: Raucherentwöhnung. Basisdokumentation für Ärztinnen und Ärzte. Verbindungen der Schweizer Ärztin-nen und Ärzte FMH und Bundesamt für Ge-sundheit (BAG), 2000.
38. 1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
39. Henningfield JE: Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196-1203.
40. Jorenby DE, Leischow SJ, Nides MA, Ren-nard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fio-re MC, Baker TB: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685-691.
41. Silagy C, Mant D, Fowler G, Lodge M: Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-142.
42. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B: Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
43. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA: Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 2009; 34: 634-640.
44. Faessel H, Ravva P, Williams K: Pharmaco-kinetics, safety, and tolerability of vareni-cline in healthy adolescent smokers: a multi-center, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009; 31: 177-189.
45. Becklake MR: Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140:S85-S91.
46. Heffner JE, Fahy B, Hilling L, Barbieri C: Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155:1055-1059.
47. Stewart MA: Effective physician-patient communication and health outcomes: a review. CMAJ 1995; 152:1423-1433.
48. Bischoff EW, Hamd DH, Sedeno M, Bene-detti A, Schermer TR, Bernard S, Maltais F, Bourbeau J: Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011; 66: 26-31.
49. Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, Thwin SS, Huang GD, Robbins R, Sriram PS, Sharafkhaneh A, Mador MJ, Sarosi G, Panos RJ, Rastogi P, Wagner TH, Mazzuca SA, Shannon C, Colling C, Liang MH, Stoller JK, Fiore L, Niewoehner DE: A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitaliza-tions: a randomized, controlled trial. Ann Intern Med 2012; 156:673-683.
50. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr: Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1136-1142.
51. Karner C, Chong J, Poole P: Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7:CD009285.
52. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of tiotro-pium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-1554.
53. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM, POET-COPD Investigators: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364:1093-1103.
54. Singh S, Loke YK, Furberg CD: Inhaled an-ticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systemic review and meta-analysis. JAMA 2008; 300: 1439-1450.
55. Michele TM, Pinheiro S, Iyasu S: The safety of tiotropium-the FDA's conclusions. N Engl J Med 2010; 363:1097-1099.
56. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE Study: Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-479.
57. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B, INTENSITY Study Investigators: Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38: 797-803.
58. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vest-bo J, TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-798.
59. Aubier M, Barnes PJ: Theophylline and phosphodiesterase inhibitors. Eur Respir J 1995; 8:347-348.
60. Calverley PM, Rabe KF, Goehring UM, Kris-tiansen S, Fabbri LM, Martinez FJ: Roflumi-last in symptomatic chronic obstructive pulmonary disease. Lancet 2009; 374: 685-694.
61. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators. Lancet 2009; 374: 695-703.
62. Callahan CM, Dittus RS, Katz BP: Oral cor-ticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991; 114: 216-223.
63. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ: Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985; 67: 56-64.
64. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ: Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988; 1:22-26.
65. Decramer M, de Bock V, Dom R: Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 1958-1964.
66. Gosselink R, Troosters T, Decramer M: Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996; 153: 976-980.
67. Senderovitz T, Vestbo J, Frandsen J, Malt-baek N, Norgaard M, Nielsen C, Kampmann JP: Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respir Med 1999; 93: 715-718.
68. Sin DD, Tashkin D, Zhang X, Radner F, Sjö-bring U, Thorén A, Calverley PM, Rennard SI: Budenoside and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
69. Paggiaro PL, Dahle R, Bakran I, Frith L, Hol-lingworth K, Efthimiou J: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-780.
70. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819-1823.
71. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953.
72. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionatein patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303.
73. Barnes PJ: Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 342-344.
74. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, Similowski T, Akkermans RP, Pasker-de Jong PC, Dekhuijzen PN, van Herwaarden CL, van Weel C: Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999; 54:7-14.
75. Rodrigo GJ, Plaza V, Castro-Rodríguez JA: Comparison of three combined pharmacological approaches with tiotropium mono-therapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012; 25:40-47.
76. Ohar JA, Donohue JF: Mono-and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med 2010; 31: 321-333.
77. Albert RK: Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-698.
78. Decramer M, Janssens W: Mucoactive therapy in COPD. Eur Resp Rev 2010; 19: 134-140.
79. Decramer M, Rutten-Van Mölken M, Dekhuijzen PN, Troosters T, van Her-waarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A: Effects of N-acetylcys-teine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365:1552-1560.
80. Steurer-Stey C, Bachmann LM, Steurer J, Tramèr MR: Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126:1645-1655.
81. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoen-ratanaku S: Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125:2011-2020.
82. Poole P, Chacko EE, Wood-Baker R, Cates CJ: Influenza vaccine for patients with chronic obstructive pulmonary disease. Co-chrane Database Syst Rev 2006;CD002733.
83. Tata LJ, West J, Harrison T, Farrington P, Smith C, Hubbard R: Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003; 58: 835-839.
84. Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, Merino M, Perez J, Lima J: Clinical efficacy of anti-pneu-mococcal vaccination in patients with COPD. Thorax 2006; 61: 189-195.
85. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinica l trial. Ann Intern Med 1980; 93: 391-398.
86. Report of the Medical Research Council Working Party: Long term domiciliary oxygen therapy in chronic hypoxic cor pulmo-nale complicating chronic bronchitis and emphysema. Lancet 1981; 1:681-686.
87. Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G: Effects of long-term oxygen therapy on pulmonary hemodynam-ics in COPD patients: a 6-year prospective study. Chest 1998; 113:65-70.
88. Guidelines for long-term home oxygen therapy in patients with chronic respiratory insufficiency. Swiss Society for Tuberculosis and Lung Diseases Control and Swiss Society of Pneumology. Schweiz Med Wochenschr 1997; 127: 871-875.
89. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heck-scher T, Viskum K, Stolk J: A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160:1468-1472.
90. Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA: Exploring the role of CT densitometry: a randomized study of augmentation therapy in alfa-1 antitrypsin defiency. Eur Respir J 2009; 33: 1345-1353.
91. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A: Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136.
92. McEvoy RD, Pierce RJ, Hillman D, Esterman A, Ellis EE, Catcheside PG, O'Donoghue FJ, Barnes DJ, Grunstein RR: Nocturnal nonin-vasive nasal ventilation in stable hypercapnic COPD: a randomized controlled trial. Thorax 2009; 64: 561-566.
93. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR: Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325-331.
94. Lacasse Y; Goldstein R, Lasserson T, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;CD003793.
95. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM: Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61:772-778.
96. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J: Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;CD005305.
97. Crisafulli E, Gorgone P, Vagaggini B, Paga-nai M, Rossi G, Costa F, Guariello V, Pag-giaro P, Chetta A, de Blasio F, Olivieri D, Fabbri LM, Clini EM: Efficacy in standard rehabilitation in COPD outpatients with co-morbidities. Eur Resp J 2010; 36:1042-1048.
98. Spencer LM, Alison JA, McKeough ZJ: Maintaining benefits following pulmonary rehabilitation: a randomized controlled trial. Eur Resp J 2010; 35: 571-577.
99. Von Leupoldt A, Taube K, Lehmann K, Fritzsche A, Magnussen H: The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest 2011; 140:730-736.
100. Maurer J, Rebbapraganda V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA: Anxiety and depression in COPD: current understanding, unanswered questions and research needs. Chest 2008; 134; 43S-56S.
101. Xu W, Collet JP, Shapiro S, Lin Y, Platt RW, Wang C, Bourbeau J: Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 2008; 178:913-920.
102. Hill K, Geist R, Goldstein RS, Lacasse Y: Anxiety and depression in end-stage COPD. Eur Respir J 2008; 31:667-677.
103. Güell R, Resqueti V, Sangenis M, Morante F, Bernardi M, Casan P, Guyatt G: Impact of pulmonary rehabilitation on psychoso-cial morbidity in patients with severe COPD. Chest 2006; 129:899-904.
104. Shoup R, Dalsky G, Warner S, Davies M, Connors M, Khan M, et al: Body composition and health-related quality of life in patients with obstructive airways disease. Eur Respir J 1997; 10:1576-1580.
105. Schols AM, Slangen J, Volovics L, Wouters FM: Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1791-1797.
106. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS: Nutritional support for individuals with COPD: a meta-analysis. Chest 2000; 117: 672-678.
107. Steiner MC, Barton RL, Singh SJ, Morgan MDL: Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 2003; 58: 745-761.
108. Laros CD, Gelissen HJ, Bergstein PG, Van den Bosch JM, Vanderschueren RG, Wes-termann CJ, Knaepen PJ: Bullectomy for giant bullae in emphysema. J Thorac Cardio-vasc Surg 1986; 91:63-70.
109. Tiong LU, Davies R, Gibson PG, Hensley MJ, Hepworth R, Lasserson TJ, Smith B: Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev 2006;CD001001.
110. Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MS, Deloney PA, Sun-daresan RS, Roper CL: Bilateral pneumec-tomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Car-diovasc Surg 1995; 109:106-116.
111. Weder W, Tutic M, Lardinois D, Jungraith-mayr W, Hillinger S, Russi E.W, Bloch KE: Persistent benefit from lung volume reduction surgery in patients with homogeneous emphysema. Ann Thorac Surg 2009; 87: 229-236.
112. National Emphysema Treatment Trial Research Group: A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073.
113. Gasparini S, Zuccatosta L, Bonifazi M, Bolliger CT: Bronchoscopic treatment of emphysema: state of the art. Respiration 2012; 84:250-263.
114. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachiery JL, Glanville AR: International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745-755.
115. Thabut G, Ravaud P, Christie JD, Castier Y, Fournier M, Mal H, Leseche G, Porcher R: Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1156-1163.
116. Eskander A, Waddell TK, Faughnan ME, Chowdhury N, Singer LG: BODE index and quality of life in advanced chronic obstructive pulmonary disease before and after lung transplantation. J Heart Lung Transplant 2011; 30: 1334-1341.
117. Gold PM: The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care 2009; 54:1040-1049.
118. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
119. Davies L, Angus RM, Calverley PM: Oral corticosteroids in patients admit ted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-460.
120. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorti-coids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947.
121. Scherr A, Blasi F, Stolz D: An update on COPD exacerbations. Minerva Pneumo-logica 2011; 50:129-146.
122. Daniels JM, Snijders D, de Graaff CS, Vla-spolder F, Jansen HM, Boersma WG: Antibiotics in addition to systemic corticoste-roids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181:150-157.
123. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F: Once daily oral oflox-acin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-control led trial. Lancet 2001; 358: 2020-2025.
124. Stolz D, Christ-Crain M, Bingisser R, Le-uppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M: Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin guidance with standard therapy. Chest 2007; 131: 9-19.
125. El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM: Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63:415-422.
126. Ram FS, Picot J, Lightowler J, Wedzicha JA: Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004;CD004104.